# US 2025/0146000 A1 · Compositions and methods of treating amyotrophic lateral sclerosis (als)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0146000 A1
- Document ID: US20250146000A1
- Status: Published application
- Kind: A1
- Application number: 18/884,711
- Filed: 2024-09-13
- Published: 2025-05-08
- Earliest claimed: 2014-11-14
- Assignees: Voyager Therapeutics, Inc.
- Applicants: Voyager Therapeutics, Inc.
- Inventors: Dinah Wen-Yee SAH; Jinzhao Hou; Mathieu E. Nonnenmacher; Pengcheng Zhou; Markus Hossbach; Jochen Deckert
- Web page: https://patentgrep.com/patent/US20250146000A1

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12Y 115/01001: Superoxide dismutase (1.15.1.1)
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2330/51: Specially adapted vectors
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.

## Claims

### Claim at position 1

1-25. (canceled)

### Claim 26

An adeno-associated viral (AAV) vector genome comprising a nucleic acid positioned between two inverted terminal repeats (ITRs), wherein the nucleic acid encodes a sense strand sequence and an antisense strand sequence of a siRNA, wherein the sense strand sequence comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the nucleotide sequences listed in Table 3, Table 11 or Table 14 and the antisense strand sequence comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the nucleotide sequences listed in Table 3, Table 11 or Table 14, and wherein the sense strand sequence and the antisense strand sequence share a region of complementarity of at least 17 nucleotides in length.

### Claim 27 (depends on 26)

The AAV vector of claim 26, wherein:
(i) the sense strand sequence and the antisense strand sequence are, independently, 21 nucleotides in length; and/or
(ii) at least one of the sense strand sequence and the antisense strand sequence comprise a 3′ overhang of at least 1 or 2 nucleotides.

### Claim 28 (depends on 26)

The AAV vector genome of claim 26, which further encodes a modulatory polynucleotide comprising the sense strand sequence and the antisense strand sequence, wherein the modulatory polynucleotide comprises:
(i) a 5′ flanking region;
(ii) a loop region; and/or
(iii) a 3′ flanking region.

### Claim 29 (depends on 26)

The AAV vector genome of claim 26, which further comprises:
(i) a promoter;
(ii) an enhancer
(iii) an intron; and/or
(iv) a polyA sequence.

### Claim 30 (depends on 26)

An adeno-associated virus (AAV) particle comprising the AAV vector genome of claim 26 and an AAV capsid protein.

### Claim 31 (depends on 30)

The AAV particle of claim 30, wherein the AAV capsid protein is an AAV9 capsid protein or variant thereof, an AAV5 capsid protein or variant thereof, or an AAVrh10 capsid protein or variant thereof.

### Claim 32

A siRNA for inhibiting expression of SOD1 comprising a sense strand sequence and an antisense strand sequence, wherein the sense strand sequence comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the nucleotide sequence of sequences listed in Table 3, Table 11 or Table 14 and the antisense strand sequence comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the nucleotide sequence of sequences listed in Table 3, Table 11 or Table 14, and wherein said sense strand sequence and antisense strand sequence share a region of complementarity of at least 17 nucleotides in length.

### Claim 33 (depends on 32)

A modulatory polynucleotide comprising the siRNA of claim 32, wherein the modulatory polynucleotide further comprises:
(i) a 5′ flanking region;
(ii) a loop region; and/or
(iii) a 3′ flanking region.

### Claim 34 (depends on 30)

A pharmaceutical composition comprising the AAV particle of claim 30, and a pharmaceutically acceptable carrier.

### Claim 35 (depends on 32)

A pharmaceutical composition comprising the siRNA of claim 32, and a pharmaceutically acceptable excipient.

### Claim 36 (depends on 30)

A method for inhibiting the expression of SOD1 gene in a cell comprising administering to the cell the AAV particle of claim 30.

### Claim 37 (depends on 32)

A method for inhibiting the expression of SOD1 gene in a cell comprising administering to the cell the siRNA of claim 32, optionally wherein the cell is
(i) a mammalian cell;
(ii) a CNS cell;
(iii) a neuron;
(iv) a motor neuron or a ventral horn motor neuron; or
(v) an astrocyte.

### Claim 38 (depends on 37)

The method of claim 37, wherein the cell is
(i) a mammalian cell;
(ii) a CNS cell;
(iii) a neuron;
(iv) a motor neuron or a ventral horn motor neuron; or
(v) an astrocyte.

### Claim 39

A method for treating and/or ameliorating amyotrophic lateral sclerosis (ALS) in a subject, the method comprising administering to the subject an AAV particle comprising an AAV vector genome comprising a nucleic acid positioned between two inverted terminal repeats (ITRs), and wherein the nucleic acid sequence encodes a sense strand sequence and an antisense strand sequence of a siRNA, wherein the sense strand sequence comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the nucleotide sequences listed in Table 3, Table 11 or Table 14 and the antisense strand sequence comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the nucleotide sequences listed in Table 3, Table 11 or Table 14; wherein the sense strand sequence and the antisense strand sequence share a region of complementarity of at least 17 nucleotides in length; thereby treating the subject.

### Claim 40 (depends on 39)

The method of claim 39, wherein the expression of SOD1 is inhibited or suppressed in a CNS cell and/or a CNS region.

### Claim 41 (depends on 40)

The method of claim 40, wherein:
(i) the CNS cell comprises a motor neuron;
(ii) the CNS region comprises a spinal cord region, a forebrain region, a midbrain region, the hindbrain region, or a combination thereof; and/or
(iii) the CNS region comprises a spinal cord region.

### Claim 42 (depends on 40)

The method of claim 40, wherein the SOD1 is a wild type SOD1, a mutated SOD1, or a combination thereof.

### Claim 43 (depends on 39)

The method of claim 39, wherein the ALS is:
(i) familial ALS;
(ii) sporadic ALS;
(iii) early stage ALS;
(iv) middle stage ALS; and/or
(v) late stage ALS.

### Claim 44 (depends on 39)

The method of claim 39, wherein the AAV particle is administered intravenously to the subject.

### Claim 45 (depends on 32)

A method of treating amyotrophic lateral sclerosis (ALS) in a subject, comprising administering to the subject, the siRNA of claim 32, thereby treating the subject.
